Short answer
Phathom Pharmaceuticals, Inc. (PHAT) filed an 8-K current report with the SEC on April 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q1 2026 financial results for quarter ended March 31, 2026.
Phathom Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 financial results for quarter ended March 31, 2026
- Press release issued April 30, 2026 and attached as Exhibit 99.1
- Results excluded from Exchange Act Section 18 filing liability under Form 8-K Item 2.02 safe harbor
Item EX-99.1 · Exhibit EX-99.1
- Q1 net revenue $58.3M, up 104% year-over-year, with gross profit $46.3M and operating loss narrowing to $15.5M
- VOQUEZNA prescriptions reached 1.35M cumulatively; Q1 volume 268,000, up 115%, with 63% insurance-covered
- SG&A fell 43% to $54.0M, supporting adjusted net loss improvement to $14.7M from $77.1M
- 2026 guidance maintained: revenue $320–$345M, gross margin approximately 80%, adjusted operating expenses $235–$255M
- Operating profitability targeted beginning Q3 2026; $180.9M cash and cash equivalents after $122.0M equity proceeds and $55.8M debt repayment
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Phathom Pharmaceuticals, Inc. 8-K filings
Get the next PHAT 8-K as it lands
Follow PHAT for push alerts, or ask the research agent what this filing means.